A provision for fast track approval in the Leahy-Smith America Invents Patent Reform Act that went into effect this week could benefit some medical device companies. Meanwhile, it seems unlikely that the immediate changes in the law will have any significant impact with the pharmaceutical and biotechnology sectors. The main reason: Companies in these areas are spending so much to get products to market already they won’t notice the fees.
